The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2021 | The genetic landscape of MDS and impact on treatment
Valeria Santini, MD, University of Florence, Florence, Italy, discusses the genomic landscape of myelodysplastic syndromes (MDS), highlighting research into the development of a scoring system for MDS which integrates the IPSS-R with the clinical and molecular characteristics of MDS. Dr Santini comments on the impact of mutations such as SF3B1 and TP53 on prognosis, as well as giving an overview of the role of biomarkers in MDS. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
